Industry News
Phosphagenics aims to raise $11.25m
Melbourne's Phosphagenics (ASX:POH, AIM:PSG) is planning to raise AUD$11.25 million via a share placement to fund its core R&D program. [ + ]
Norwood Immunology to seek IPO in US
Immune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has revealed plans to seek an initial public offering (IPO) in the USA, subject to market conditions. [ + ]
CyGenics to team with Johns Hopkins
Cell therapy company CyGenics (ASX:CYN) and Johns Hopkins University School of Medicine have entered into a collaborative research agreement as part of a pre-clinical study directed at a new treatment strategy for patients with acute myeloid leukaemia (AML). [ + ]
Starpharma raises $15m
Melbourne drug developer Starpharma (ASX:SPL) has successfully raised AUD$12 million through an institutional placement at $0.51 and an additional $3 million following an underwritten share purchase plan. [ + ]
Study supports Prima vaccine effectiveness
A research report in the international journal Vaccine this month has confirmed the immunity-boosting potency of Prima Biomed's (ASX:PRR) novel DCtag adjuvant technology for veterinary vaccines. [ + ]
Setback for Rockeby in US
After a meeting with officials of the US Food and Drug Administration, fungal infection diagnostics specialist Rockeby Biomed (ASX:RBY) has mothballed its attempt to register its point-of-care CanDia5 test for vaginal thrush infection (candidiasis) for use in the US. [ + ]
Pharmaxis completes capital raising
Pharmaxis (ASX:PXS, Nasdaq:PXSL) has completed its capital raising of AUD$87 million (US$63 million). [ + ]
Canola taskforce finds small contamination
The taskforce appointed by the Australian Oilseeds Federation and the Australian Seeds Federation to investigate the recent detection of genetically modified canola seed in a small, non-GM shipment has found the contamination was limited to just one commercial cultivar. [ + ]
BioMD acquires tissue engineering company
Perth-based medical device and materials company BioMD (ASX:BOD) has paid AUD$650,000 to acquire a 50 per cent equity interest in unlisted tissue engineering company Celxcel. [ + ]
ICT Research Groups develop a research collaboration
Australia's leading ICT research groups have announced the formation of a collaboration to develop advanced information-sharing technology.
[ + ]Glygen appoints ProteoMass
Glygen Corp, specialist in life science sample preparation and delivery tools, has appointed ProteoMass Australia as its exclusive distributor for Australia.
[ + ]Xenome builds team, strengthens US ties
Unlisted Brisbane biotech Xenome is making a strong push into San Diego, hub of the US West Coast biotech industry, in pursuit of venture capital and big pharma partners to develop its long and diverse pipeline of conotoxin peptides from the venom of Australian cone shells. [ + ]
Keith Williams retires as Proteome director, remains as consultant
Proteome Systems (ASX:PXL) founder Dr Keith Williams is no longer a director of the company he established in 1999, following his decision to withdraw his nomination for re-election at yesterday's AGM. [ + ]
French order for Relenza triples cumulative global sales
A French government announcement that it would increase its pandemic stockpile of Relenza from 200,000 units to 9 million units over the next two years has sent shares in Melbourne-based Biota Holding's (ASX:BTA) up by more than 20 per cent. [ + ]
Solbec earns orphan drug status for carcinoma treatment
Solbec Pharmaceuticals (ASX:SBP) has received orphan drug designation from the US Food and Drug Administration for its lead anti-cancer compound Coramsine for the treatment of metastatic renal cell carcinoma (mRCC). [ + ]
